Phase II study of prolonged oral VP-16 for advanced ovarian epithelial and cervical cancer.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Etoposide (Primary)
- Indications Cervical cancer; Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2013 Biomarkers information updated
- 07 Jun 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 19 Sep 2005 New trial record.